Mumps Virus Vaccines for Mumps
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests two new mumps vaccines, CVM150 and CVM26, to determine their safety and ability to help the body defend against mumps. Mumps is a contagious viral infection that causes swelling of the glands around the neck. Individuals who have previously received two doses of the mumps vaccine as children and are generally healthy are suitable for this study. Participants will receive either one of the new vaccines or a placebo, a harmless substance with no effect. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive these new vaccines.
Will I have to stop taking my current medications?
The trial does not require you to stop taking your current medications as long as they are stable and do not pose additional risks or interfere with the trial. However, any changes in medication should not be due to a worsening condition, and you should discuss your specific situation with the trial investigator.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that live weakened mumps vaccines, such as CVM150 and CVM26, are generally safe. In past studies, only about 2.13% of participants experienced side effects, most of which were mild and resolved quickly. This suggests that both CVM150 and CVM26 are likely well-tolerated by most people. However, as this trial is in its early stages and primarily focuses on safety, additional information may be needed to confirm these early findings.12345
Why are researchers excited about this trial's treatments?
Researchers are excited about these mumps vaccines, CVM150 and CVM26, because they offer unique approaches compared to current options like the MMR (measles, mumps, rubella) vaccine. CVM150 is distinct because it uses a live PIV5-based vaccine that expresses specific proteins from the Iowa strain of the mumps virus, potentially enhancing immune response. On the other hand, CVM26 is genetically edited to remove certain viral protein expressions, which might improve safety and efficacy. These innovative approaches could lead to better protection against mumps, sparking excitement in the scientific community.
What evidence suggests that this trial's treatments could be effective for mumps?
Studies have shown that traditional mumps vaccines, such as the MMR (measles-mumps-rubella) vaccine, are about 88% effective after two doses. However, this protection typically decreases around 27 years after vaccination. This trial tests CVM150 and CVM26, new experimental vaccines, to determine if they offer strong protection against mumps. CVM150 uses a virus-based method to create proteins that trigger an immune response, while CVM26 is a live, weakened version of the virus with some proteins removed. These vaccines aim to help the body's immune system recognize and fight the mumps virus more effectively. Early research suggests that these new vaccines could provide protection similar to or better than current vaccines.16789
Who Is on the Research Team?
Hong Jin
Principal Investigator
CyanVac LLC
Are You a Good Fit for This Trial?
This trial is for up to 60 healthy adults. Specific eligibility criteria are not provided, but typically participants should have no underlying health conditions that could affect the outcome of the vaccine study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single intranasal dose of CVM150, CVM26, or placebo on Day 1
Follow-up
Participants are monitored for safety and immunogenicity, including local and systemic reactogenicity, immune response, and adverse events
What Are the Treatments Tested in This Trial?
Interventions
- CVM150
- CVM26
Find a Clinic Near You
Who Is Running the Clinical Trial?
CyanVac LLC
Lead Sponsor